

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
6 September 2002 (06.09.2002)

PCT


(10) International Publication Number
WO 02/067937 A1

- (51) International Patent Classification⁷: **A61K 31/47**, (74) Agent: **GILL JENNINGS & EVERY**; Broadgate House, 31/40, C07D 215/08
- (21) International Application Number: PCT/GB02/00785 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 22 February 2002 (22.02.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 01301609.2 22 February 2001 (22.02.2001) EP (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): **SCHOOL OF PHARMACY, UNIVERSITY OF LONDON** [GB/GB]; 29-39 Brunswick Square, London WC1N 1AX (GB).
- (72) Inventors; and (75) Inventors/Applicants (*for US only*): **SEARCEY, Mark** [GB/GB]; School of Pharmacy, University of London, 29-39 Brunswick Square, London WC1N 1AX (GB). **PATTERSON, Laurence, Hylton** [GB/GB]; School of Pharmacy, University of London, 29-39 Brunswick Square, London WC1N 1AX (GB).
- Published:**
— *with international search report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: INDOLINE AND TETRAHYDRO-QUINOLINES AS PRODRUGS FOR TUMOUR TREATMENT



(57) Abstract: Compounds of the general formula I or IA or a salt in which X is H, Y is a leaving group, R¹ preferably being an aromatic DNA binding subunit are prodrug analogues of duocarmycin. The compounds are expected to be hydroxylated at the carbon atom to which X is joined, by cytochrome P450, in particular by CYP1B1, expressed at high levels in tumours. The prodrug is expected to be activated preferentially in tumour cells, where it will act as a DNA alkylating agent preventing cell division.



WO 02/067937 A1

INDOLINE AND TETRAHYDRO-QUINOLINES AS PRODRUGS FOR TUMOUR TREATMENT

The present invention concerns aromatic oxidation/hydroxylation activated prodrugs, particularly anti-tumour prodrugs and those which are specifically activated by the oxidation/hydroxylation activities of the cytochrome P450 family of enzymes.

Many conventional cytotoxic drugs are known that can be used for therapeutic purposes. However, they typically suffer from the problem that they are generally cytotoxic and therefore may affect cells other than those that are required to be destroyed. This can be alleviated to some extent by the use of targeted drug delivery systems, for example direct injection to a site of tumourous tissue or, e.g. binding the cytotoxic agent to an antibody that specifically recognises an antigen displayed only on the cancer cell surface. Alternatively, electromagnetic radiation may be used to cause chemical alteration in an agent at a desired site such that it becomes cytotoxic. However, all of these techniques have, to a greater or lesser extent, certain limitations and disadvantages.


The compound (+)-CC-1065 and the duocarmycins are naturally occurring representatives of a class of DNA alkylating agents. The naturally occurring compounds consist of a DNA alkylating unit based upon a pyrrolo[3,2-e]indole core, with one or two sub units, conferring DNA binding capabilities. CC-1065 and duocarmycin A comprise a spirocyclic cyclopropane group responsible for the DNA alkylation properties. Duocarmycin B₂, C₂ and D₂ are believed to be precursors for cyclopropane actives, and comprise a substituted (by a leaving group) methyl group at the eight position on the dihydro pyrrole ring. CC-1065 has been synthesised by various routes, summarised by Boger *et al* in Chem. Rev. 1997, 97, 787-828.

In US-A-4413132 the first synthesis of the left hand sub-unit of CC-1065 was described. The synthesis is based on a Winstein Ar-3' alkylation in which the cyclopropane ring is introduced. In a previous step, the A ring (of the indole core) is introduced by reaction of an aniline with an α -thiomethylester using chemistry based on Gassman's Oxindole Synthesis. The aniline has a protected phenolic hydroxyl group ortho to the NH₂ group,

which, in the final product, is believed to be crucial for DNA alkylation. CC-1065 has broad antitumour activity but is too toxic against normal cells to be clinically useful.

Attempts have been made to target the delivery of CC-1065 and analogues by conjugating the drug via the DNA binding subunit to polymers, or specific binding agents such as antibodies or biotin described in US 5,843,937. Boger *et al* in Synthesis 1999 SI, 1505-1509 described prodrugs of 1,2,9,9a-tetrahydrocyclopropa(c)benz[e]indol-4-one, in which the cyclopropane ring-opened version of the compounds were derivatised by reaction of the phenolic group to form esters and carbamates.

In Tet. Letts. (1998) 39, 2227-2230 Boger *et al* describe the synthesis of some CC-1065 analogues including the compound



in which OMOM is an alkoxy alkoxy group. The compound is proposed as a precursor of a mitomycin hybrid, ie the cyclopropane-ring-closed indoline form.

In J.Am.Chem.Soc. (1991), 113, 3980-'83 Boger *et al* describe a study to identify features of CC-1065 analogues contributing to the selectivity of the DNA-alkylation. The compounds tested *in vitro* had alkylating subunits based on 2,3-dihydroindole and included the 6-deshydroxy analogues. These were shown to have some DNA alkylating properties though at concentrations 10^4 times higher than that of the 6-hydroxy compounds.

The present invention relates to precursors of analogues of CC-1065 which are indole derivatives, which do not have the hydroxyl group in the benzene ring of indole alkylating sub unit, and which are hence substantially inactive as DNA alkylating agents themselves.

It has been reported (Murray, G.I. *et al.*, 15 July 1997, Cancer Research, 57m 3026-3031 and WO-A-9712246) that the enzyme CYP1B1, a

member of the cytochrome P450 (CYP) family of xenobiotic metabolising enzymes, is expressed at a high frequency in a range of human cancers, including cancers of the breast, colon, lung, oesophagus, skin, lymph node, brain and testes, and that it is not detectable in normal tissues. This led to the conclusion that the expression of cytochrome P450 isoforms in tumour cells provides a molecular target for the development of new antitumour drugs that could be selectively activated by the CYP enzymes in tumour cells, although no drug examples were given. A number of other CYP isoforms have been shown to be over expressed in various tumours.


Many of the CYP's expressed in tumours are mentioned in Patterson, LH *et al*, (1999) Anticancer Drug Des. 14(6), 473-486.

In WO-A-99/40056 prodrugs of styrene- and chalcone-derivatives are described. The respective hydroxylated forms of the prodrugs, formed *in situ*, are potent tyrosine kinase (TK) inhibitors. Inhibition of TK activity contributes to tumour inhibition and cell destruction. The prodrugs were shown to be activated by microsomal preparations expressing CYP1B1 enzyme, and to have cytotoxic activity against cell lines expressing the same enzyme, whilst having much lower cytotoxic activity against cell lines not expressing the enzyme.

The present invention is directed to a new class of prodrugs which are expected to be hydroxylated *in situ* by CYP enzymes, in particular enzymes expressed at high levels in tumours as described by Patterson LH, *et al*, *op. cit.*. In particular the prodrugs are believed to be metabolisable by CYP1B1 enzyme. Some of the compounds are new. The present invention relates to the first therapeutic use of a broad range of compounds.


There is provided according to the first aspect of the invention the new use of a compound of the general formula I or IA or a salt thereof in the manufacture of a composition for use in a method of treatment by therapy of an animal:

4



I

5



IA

10

in which X is H;

Y is a leaving group; (preferably selected from OCOOR^5 , OCONHR^6 ,
 15 Cl, Br, I and OSO_2R^7 in which R^5 , R^6 , and R^7 are each selected from C_{1-4}
 alkyl, optionally substituted phenyl, C_{1-12} aralkyl and optionally substituted
 heteroaryl);

R^1 is -Ar, NH_2 , R^8 or OR^8 ;


R^2 and R^3 are each independently selected from H, C_{1-4} alkyl, -OH,
 20 C_{1-4} alkoxy, -CN, Cl, Br, I, $-\text{NO}_2$, $-\text{NH}_2$, $-\text{NHCOR}^9$, $-\text{COOH}$, $-\text{CONHR}^{10}$, -
 NHCOOR^{10} and $-\text{COOR}^{10}$;

R^4 is selected from H, C_{1-4} alkyl, CN, Cl, Br, I, NO_2 , NH_2 , $-\text{NHCOR}^9$,
 $-\text{COOH}$, $-\text{CONHR}^{10}$, $-\text{NHCOOR}^{10}$ and $-\text{COOR}^{10}$;

R^8 , R^9 and R^{10} are independently selected from C_{1-4} alkyl, optionally
 25 substituted phenyl, C_{7-12} -aralkyl and optionally substituted heteroaryl and
 ligands;

Ar is selected from

5



in which B is N or CR¹⁴;

Z is O, S -CH=CH- or NH;

the or each R¹¹ is selected from OH, C₁₋₄ alkoxy, C₁₋₄ alkyl, -NO₂, -NH₂, -NHR¹⁷, -NR¹⁷₂, -N⁺R¹⁷₃, -CN, Cl, Br, I, -NHCOR¹⁵, -COOH, -CONHR¹⁶, -NHCOOR¹⁶ and COOR¹⁶;

n is an integer in the range 0 to 4;

R¹² is H, -COAr¹, -CONH₂, -COOH, -COR¹⁶ or -COOR¹⁶;

the or each R¹³ is selected from OH, C₁₋₄ alkoxy, C₁₋₄ alkyl, -NO₂, -NH₂, -NHR¹⁷, -NR¹⁷₂, -N⁺R¹⁷₃, -CN, Cl, Br, I, -NHCOR¹⁵, -COOH, -CONHR¹⁶, -NHCOOR¹⁶ and -COOR¹⁶;

m is 0, 1 or 2;

R¹⁴ is selected from OH, C₁₋₄ alkoxy, C₁₋₄ alkyl, -NO₂, -NH₂, -CN, Cl, Br, I, -NHCOR¹⁵, -COOH, -CONHR¹⁶, -COOR¹⁶, -NHCOOR¹⁶ and H;

R¹⁵ is selected from C₁₋₄ alkyl, optionally substituted phenyl, optionally substituted heteroaryl, C₇₋₁₂ aralkyl, a ligand and Ar¹;

R¹⁶ is selected from C₁₋₄ alkyl, optionally substituted phenyl, C₇₋₁₂-aralkyl and optionally substituted heteroaryl and a ligand;

each R¹⁷ is selected from C₁₋₄ alkyl, optionally substituted phenyl, optionally substituted heteroaryl and C₇₋₁₂-aralkyl; and

Ar¹ is selected from the same groups as Ar,

provided that no more than one group R¹¹ or R¹³ in any one ring includes a group Ar¹.


The animal which is treated is generally a human, although the compounds may also have veterinary use. The indication treated is generally cancer including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus. The tumour may, for instance, be defined as a tumour expressing high levels of CYP1B1.

In the invention, the leaving group Y is, for instance, a leaving group which has utility in nucleophilic substitution reactions. Suitable examples of such groups are $-\text{OCOOR}^5$, $-\text{CONHR}^6$, Cl, Br, I, or $-\text{OSOOR}^7$, in which R^5 , R^6 and R^7 are each selected from C_{1-4} alkyl, optionally substituted phenyl, C_{7-12} -aralkyl and optionally substituted heteroaryl. Most preferably the leaving group is a halogen atom, preferably chlorine.

Optional substituents in phenyl, aralkyl and heteroaryl groups are, for instance, C_{1-4} -alkyl, halogen, hydroxyl, C_{1-4} -alkoxy, $-\text{NH}_2$, $-\text{NHR}^{17}$, $-\text{NR}^{17}_2$, $-\text{N}^+\text{R}^{17}_3$, $-\text{NO}_2$, $-\text{CN}$, $-\text{COOH}$, $-\text{NHCOR}^{15}$, $-\text{CONHR}^{16}$, $-\text{NHCOOR}^{16}$, $-\text{COOR}^{16}$ etc.


In the present invention the term ligand includes a group having specific targeting characteristics, useful for instance in antibody or gene-directed enzyme prodrug-type environments. A ligand may be an oligopeptide, biotin, avidin or streptavidin, a polymeric group, an oligonucleotide or a protein. Preferably it has specific binding characteristics such as an antibody or fragment, an antigen, a sense or anti-sense oligo-nucleotide, or one of avidin, streptavidin and biotin, that is it is one component of a specific binding pair. Alternatively it may be a group designed for passive targeting, such as a polymeric group, or a group designed to prolong the stability or reduce immunogenicity such as a hydrophilic group. US-A-5843937 discloses suitable ligands for conjugating to these types of actives and methods for carrying out the conjugation.

The group Ar^1 is preferably



Preferably R^1 is other than $-OR^8$ in a pharmaceutically active compound. In general, for optimised DNA binding ability, the group R^1 in a compound of the general formula I or IA is a group Ar. Often the compound may include two aromatic groups joined to one another. In such compounds, one of the groups R^{11} of the Ar group, or the group R^{12} , as the case may be, is a group Ar^1 . Whilst for some compounds it may be desirable for three or more such aromatic groups to be linked, it is preferred that there is one group Ar and one group Ar^1 . Thus in a group Ar^1 which is a pyrrolo-dihydroindole type of group, the group R^{12} should be other than a group $COAr^1$. In a group Ar^1 which is one of the other types of groups there should either be no substituents R^{11} or R^{13} , as the case may be, or, if there are any substituents, no such substituent should include a group Ar^1 .


According to one embodiment of the invention, the substituent Ar is a group



In such groups Ar, B is preferably CR^{14} . R^{14} is preferably H. The definition of Z is preferably NH, although furan ($Z=O$) and thiophene ($Z=S$) analogues had been generated for conjugation to DNA alkylating units and may have useful DNA binding characteristics. Similarly, in a group Ar^1 , the groups B and Z are selected amongst the same preferable groups.

Preferably n is at least 1 and one of the groups R^{11} is $-NHCOAr^1$. In this embodiment Ar^1 is preferably a group


8



5 in which B and Z are the same as in Ar.

In another embodiment the substituent Ar is a group

10



15

Preferably R^{12} in such a group Ar is other than COOR^{16} , more preferably it is a group $-\text{COAr}^1$, in which Ar^1 preferably is the same type of group.

In both groups Ar and Ar^1 , m in the indole type group is preferably zero.

In Ar and Ar^1 , there may be several substituents R^{11} . Most preferably such substituents are selected amongst C_{1-4} -alkoxy groups.

20

In compounds of the formula I, the core benzene ring of the DNA alkylating sub-unit is preferably unsubstituted (R^3 and R^4 are both hydrogen).

25

In the compounds of the formula I, X is H. It is believed that, hydroxylation of the compound will occur *in situ* at the carbon atom to which X is attached, thereby activating the compound enabling it to act as a DNA alkylating agent.

30

The present invention further provides pharmaceutical compositions comprising compounds of the formula I and IA or salts and a pharmaceutically acceptable excipient. Pharmaceutical compositions may be suitable for intramuscular, intraperitoneal, intrapulmonary, oral or, most preferably, intravenous administration. The compositions contain suitable matrixes, for example for controlled or delayed release. The compositions

may be in the form of solutions, solids, for instance powders, tablets or implants, and may comprise the compound of the formula I in solid or dissolved form. The compound may be incorporated in a particulate drug delivery system, for instance in a liquid formulation. Specific examples of suitable excipients include lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate. Solid compositions may take the form of powders and gels but are more conveniently of a formed type, for example as tablets, cachets or capsules (including spansules). Alternative, more specialised types of formulation including liposomes, nanosomes and nanoparticles.


It is believed that compounds of the general formula IA may be novel compounds.

One compound of the general formula I (in which R^1 is -O-tBu, R^2 , R^3 and R^4 are all H, and Y is OSO_2CH_3) was synthesised by Boger *et al*, J.Am. Chem. Soc (1991) 113, 3980-5983. Others may be made by analogous techniques. It is convenient to form the DNA alkylating sub unit in one series of steps and to attach this through the nitrogen atom of the dihydro-pyrrole or tetrahydroquinoline as the case may be, ring to the rest of the molecule. The DNA alkylating sub-unit may be conjugated to DNA binding sub-units synthesised as described in Boger *et al*, 1997 *op. cit.*, for instance the PDE-I and PDE-II sub-units described in that reference.

The compounds of the formula I and IA may be synthesised in a method in which a compound of the formula II or IIA, as the case may be,


10

5



II

10



IIA

in which X, R², R³ and R⁴ are as defined above; and

Y¹ is a leaving group or is hydroxyl;

15




is reacted with a compound of the general formula III




III

in which R¹⁸ is selected from C₁₋₄-alkyl, optionally substituted phenyl, C₇₋₁₂-aralkyl, optionally substituted heteroaryl and Ar²;

Ar² is selected from



and



20

in which B¹ is N or CR²³;

Z¹ is O, S, -CH=CH- or NR²⁴;

the or each R¹⁹ is selected from C₁₋₄-alkoxy, C₁₋₄-alkyl, NO₂, CN, Cl, Br, I, -NHR²⁴, -NR²⁵₂, -N⁺R²⁵₃⁻, I, -NHCOR²⁶, -COOH, -CONHR²⁷ and -

5 COOR²⁷;

p is an integer in the range 0 to 4;

R²⁰ is an amine protecting group;

R²¹ is an amine protecting group, -CONH₂, -COOH, -COR²⁷ or -COAr³;

10 the or each R²⁰ is selected from C₁₋₄-alkoxy, C₁₋₄-alkyl, NO₂, CN, Cl, Br, I, -NHR²⁴, -NR²⁵₂, -N⁺R²⁵₃⁻, NHCOR²⁶, -COOH, -CONHR²⁷ and -COOR²⁷;

q is 0, 1 or 2;

R²³ is selected from H, C₁₋₄-alkoxy, C₁₋₄-alkyl, NO₂, CN, Cl, Br, I, -NHR²⁴, -NR²⁵₂, -N⁺R²⁵₃⁻, NHCOR²⁶, COOH, -CONHR²⁷ and COOR²⁷;

R²⁴ is an amine protecting group;

15 R²⁶ is selected from Ar³, C₁₋₄-alkyl, optionally substituted phenyl, C₇₋₁₂-aralkyl, optionally substituted heteroaryl and a ligand;

each R²⁵ is selected from H, C₁₋₄-alkyl, optionally substituted phenyl, C₇₋₁₂-aralkyl and optionally substituted heteroaryl;


20 R²⁶ is selected from C₁₋₄-alkyl, optionally substituted phenyl, C₇₋₁₂-aralkyl optionally substituted heteroaryl and a ligand;

Ar³ is selected from the same groups as Ar²;

and Y² is a leaving group,

provided that no more than one R¹⁹ or R²² in any one ring includes a group Ar³.

25 Preferably a group Ar³ is



Y^2 is, for instance, selected amongst the preferred leaving groups listed above for Y. Most suitably the definition of Y^2 is Cl. Alternatively, the group Y^2 may be OH. In this case, it may be necessary to include a coupling agent to assist in the coupling reaction.

- 5 Y^1 may be the same as Y or may be another leaving group, or hydroxyl, which may be converted to Y in a subsequent step.

The reaction between the compound of the general formula II or A, as the case may be, and the carboxylic acid or derivative of the general formula II is carried out under conditions allowing such coupling to take place. Such
10 conditions are similar to those generally used for formation of peptide bonds, for instance as used in peptide synthetic methods.


After the coupling process, it may be desirable to deprotect one or more of any protected amine groups. If further reaction, for instance with other derivatising agents such as glycosyl compounds, peptides, polymers
15 etc is desired through any such amine groups, it may be desirable to deprotect only those to which subsequent reaction is to take place, whilst retaining the other amine groups in a protected form. Selection of suitable amine protecting groups and protection and deprotection protocols may be made using techniques commonly utilised in peptide chemistry.

20 The compound of the formula II or IIA may be prepared in a preliminary step including a cyclisation step in the presence of a catalyst using as the starting material an aniline compound having a leaving group substituent Y^3 at the carbon atom ortho to the amine group substituent, and an N-substituent which is a group $-CH_2CH=CHY^4$, in which the aniline
25 derivative is reacted under cyclisation conditions, to form a dihydropyrrole or di- or tetrahydroquinoline ring.

The starting compound for such a cyclisation reaction may be represented by the general formula IV

13

5



IV

10 in which R^2 , R^3 , R^4 , X^4 and Y^1 are the same as in the compound of the formula II;

R^{28} is an amine protecting group,

one of Z^1 and Z^2 is Y^4 and the other is H;

Y^4 is H, or is a leaving group which is different from or the same as Y^1 ;

and

15 Y^3 is a radical leaving group.

Y^3 is preferably a halogen atom, more preferably Br or I.

When cyclisation to form a dihydropyrrole ring is desired, the group Z^1 is Y^4 , and Y^4 is either H or a leaving group, preferably the same group as Y^1 . (In this reaction Y^4 is not active as a leaving group but may be so in subsequent steps of the synthesis.) The reaction is conducted in the presence of a suitable catalyst, optionally in the presence of a free radical trap. A group Y^4 is preferably I. Where Y^4 is a leaving group the cyclisation may be carried out in the presence of radical derived from azoisobutyronitrile. Suitable catalysts for such a radical cyclisation step are tin hydride compounds such as tributyl tin hydride. Such a synthetic route is illustrated in Example 1.

Suitable radicals for carrying out the cyclisation reaction using a compound IV in which Y^4 is H are nitroxyl compounds such as 2,2,6,6-tetramethylpiperidinyloxy (TEMPO) radical.

30 For cyclisation to form a six-membered ring it is preferred to use a compound IV in which Z^2 is Y^4 and Y^4 is a leaving group, preferably a trialkyl stannyl group, and to carry out the reaction in the presence of a suitable

catalyst palladium complexes such as tetrakis (triphenylphosphine) palladium (0), bis(triphenyl phosphine) palladium (II) chloride or palladium (II) acetate. In this reaction Y⁴ is active as a leaving group. The dihydroquinoline intermediate is oxidised to form a further intermediate which is an epoxide, for instance using a peroxide reagent. The epoxide intermediate is reduced using a suitable selective reducing agent such as a dialkyl aluminium hydride to produce the corresponding tetrahydroquinoline alcohol which is subsequently halogenated, for instance using carbon tetrachloride/triphenyl phosphine. This reaction is illustrated in Example 2.

10 The compound of the general formula IV may be produced by alkylation of the sodium salt of the corresponding amiline derivative with a trans-1,3-dihaloprop-2-ene compound.

15 The carboxylic acid derivative of the general formula III may be synthesised using the methods generally described in Boger *et al*, 1997 *op.cit.*, for instance PDE-I and PDE-II may be synthesised using the Umezawa synthesis, the Rees-Moody synthesis, the Magnus synthesis, the Cava-Rawal synthesis, the Boger-Coleman synthesis, the Sundberg synthesis, the Martin synthesis, the Tojo synthesis. Indole-2-carboxylic acid is commercially available. Other analogues of the DNA binding sub-units of the duocarmycins, and reactive carboxylic acid derivatives thereof are described by Boger *et al*, *op.cit.* and in US-A-5843937.

20 The present invention relates to the creation of a range of prodrugs that have little or no cytotoxic effects when in their normal state, but are highly cytotoxic (i.e. have a substantially increased cytotoxicity) when activated by oxidation or hydroxylation by CYP enzymes. This provides for a self-targeting drug delivery system in which a non cytotoxic (or negligibly cytotoxic) compound can be administered to a patient, for example in a systemic manner, the compound then being activated at the site of the tumour cells (intratumoural activation) to form a highly cytotoxic compound which acts to kill the tumour cells. The fact that the CYP isoforms are not expressed by normal cells mean that the activation of the compound only

25

30

occurs at the site of the tumour cells and therefore only tumour cells are affected, thus providing a self-targeting system.

The prodrugs of the present invention have the distinct advantage of being useful in the treatment of tumours at any site in the body, meaning that
5 even tumours that have undergone metastasis (which are normally not susceptible to site specific therapies) may be treated.

The prodrug may be an antitumour prodrug. Examples of tumours include cancers (malignant neoplasms) as well as other neoplasms e.g. innocent tumours. The prodrug may be activated by hydroxylation by
10 isoforms of cytochrome P450's. In a variation of the normal procedure which relies upon CYP expression within tumour cells to effect selective hydroxylation and hence activation of the prodrugs, the selectivity between tumour tissue and normal tissue can be enhanced in a two part procedure. Thus (a) infecting tumor cells with a viral vector carrying a cytochrome P450
15 gene and a cytochrome P450 reductase gene, wherein expression of cytochrome P450 gene and cytochrome P450 reductase gene by tumor cells enables the enzymatic conversion of a chemotherapeutic agent to its cytotoxic form within the tumor, whereby the tumor cells become selectively sensitized to the prodrug chemotherapeutic agent (b) contacting tumor cells
20 with the prodrug chemotherapeutic agent whereby tumor cells are selectively killed.

Thus the intratumoural hydroxylation of the prodrugs of the present invention provides them with a surprising and unexpected efficacy.


Hydroxylated forms of the prodrugs are potent DNA alkylating agents
25 that bind in the minor groove of DNA and alkylate the purine bases at the N3 position. As such, they are potent cytotoxic agents whose exact biological mechanism of action is unknown but involves the disruption of template and other functions of DNA. General inhibition of template function of DNA will affect and be generally cytotoxic to all dividing cells in the body and lead to
30 unacceptable side effects in a therapeutic setting. However, the targeted production of hydroxylated forms only in tumour cells that overexpress particular isoforms of cytochrome P450's will lead to a specific cytotoxic

effect only in those cells. The non-hydroxylated forms are essentially non-toxic to all cells.

The following examples illustrate the invention.

Example 1

- 5 The synthesis of one compound of the general formula I is carried out according to the following reaction scheme.



1.1 1-((*tert*-Butyloxy)carbonyl)amino-2-iodobenzene

- A mixture of 2-iodoaniline (100 mg, 0.46 mmol), dichloromethane (DCM) (4ml), di-tertiary butyl dicarbonate (BOC- dicarbonate) (119 mg, 0.55 mmol),
 10 Et_3N (76 μl , 0.55 mmol) and catalytic (dimethylamino) pyridine (DMAP) (2mg) was stirred for 20 hrs. The reaction was concentrated and purified by flash chromatography 4-(DCM/Hex are 1:1) to afford the product (50 mg, 34%) as a off white powdery solid.

- 1.2 1-*N*-(Chloro-2-propen-1-yl)-*N*-((*tert*-butyloxy)carbonyl)amino-2-iodobenzene**
 15

- A stirred solution of 1-((*tert*-butyloxy)carbonyl)amino-2-iodobenzene (100 mg, 0.31 mmol) in DMF (dimethyl formamide) (2 ml) was cooled to 0°C and treated with sodium hydride (NaH) (41 mg, 1.0 mmol). After 15 min, 1,3-dichloropropene (95 μl , 1.01 mmol) was added. The mixture was allowed to
 20 warm to 25 °C and stirred for 20 hrs. It was concentrated, H_2O (10 ml) was added and the aqueous layer was extracted with EtOAc (3 x 10ml). The

combined organic layers were dried (MgSO_4) and concentrated. The residue was purified by flash chromatography (Silica gel, 1 to 10% EtOAc/Hexanes gradient) to furnish the title compound (46 mg, 37%) as a yellow oil.

5 **1.3 3-Chloromethyl-2,2-dihydro-1-((*tert*-butyloxy)carbonyl)indole**

A stirred mixture of 1-*N*-(3-Chloro-2-propen-1-yl)-*N*-((*tert*-butyloxy)carbonyl)amino-2-iodobenzene (200 mg, 0.51 mmol), $(\text{Bu}_3\text{Sn})_2\text{O}$ (38 μL , 0.076 mmol), poly(methylhydrosiloxane) (PMHS) (1439 μL , 0.019 mmol), azoisobutyronitrile (AIBN) (8.34 mg, 0.051 mmol) in toluene (4 mL) was heated under N_2 for 3h at 80°C. The reaction was cooled and quenched with EtOAc (20 mL). The solution was washed with water (2 x 20 mL), dried (MgSO_4) and concentrated. The residue was purified by chromatography (Silica, 1 to 10% EtOAc/Hexanes) to afford the title compound (159 mg, 85.5%) as a clear oil.

15 **1.4 5-Methoxyindole extended agent. 1-(chloromethyl)-6-benzoyl-3-((5-methoxy-1*H*-indol-2-yl)carbonyl)-1,2-dihydro-3*H*-pyrrolo[3,2-*e*]indole**


3-Chloromethyl-2,2-dihydro-1-((*tert*-butyloxy)carbonyl)indole (100 mg, 0.37 mmol) is treated with a solution of hydrochloric acid in ethyl acetate (4M, 500 μL). After 30 min, the solvent is concentrated and DMF (1 mL) is added. The solution was treated with 1-[(3-dimethylamino)propyl]-3-ethylcarbodiimide (EDC) (140 mg, 0.73 mmol) and 5-methoxyindole-2-carboxylic acid (140 mg, 0.73 mmol).

After 16 h, the solvent was removed under reduced pressure. Chromatography (Silica gel, 2 x 15 cm, 10% ethyl acetate/hexanes) gave the product.

25 **Example 2**

The following example illustrates the synthesis of a precursor of a compound of the general formula IA. The product is suitable for extending by a step analogous to step 1.4 to form a compound of the formula IA.

18



2.1 1-*N*-(3-(tributylstannyl)-2-propen-1-yl)-*N*-((*tert*-butyloxy)carbonyl)amino-2-iodobenzene

1-((*tert*-butyloxy)carbonyl)amino-2-iodobenzene (synthesised as set out in
 5 example 1.1) (100 mg, 0.32 mmol) was stirred in DMF (5 mL) and sodium
 hydride (38 mg, 0.96 mmol, 60% dispersion in oil, 3 equiv.) was added. After
 15 min, the suspension was treated with E/Z-1-tributylstannyl-3-
 bromopropene (392 mg, 0.92 mmol, 3 equiv) and the resulting solution was
 stirred at RT for 16 h. The solution was concentrated and water (10 mL) was
 10 added. The aqueous solution was extracted with ethyl acetate (3 x 10 mL),
 the organic layers combined, dried and concentrated. The product (145 mg,
 70%) was obtained after chromatography (Silica gel, 2 x 15 cm, 10% ethyl
 acetate/hexanes). FABMS (NBA/NaI) 649 ($M + H^+$ expected 649).

2.2 1-((*tert*-butyloxy)carbonyl)-1,2-dihydroquinoline

1-*N*-(3-(tributylstannyl)-2-propen-1-yl)-*N*-((*tert*-butyloxy)carbonyl)amino-2-
 15 iodobenzene (100 mg, 0.15 mmol) and tetrakis(triphenylphosphine)
 palladium(0) (32 mg, 0.2 equiv) were stirred in toluene (2 mL) at 50°C under
 N_2 for 12 h. The solvent was then removed *in vacuo*. Chromatography (SiO_2 ,
 10% ethyl acetate/hexanes) gave the product (35 mg, 100%) as a yellow oil.
 20 FABMS (NBA/NaI) 232 ($M + H^+$ expected 232).

2.3 1-((*tert*-Butyloxy)carbonyl)-3,4-epoxy-1,2,3,4-tetrahydroquinoline

1-((*tert*-Butyloxy)carbonyl)-1,2-dihydroquinoline (100 mg, 0.43 mmol) and
 MCPBA (109 mg, 0.65 mmol, 1.5 equiv) were stirred in CH_2Cl_2 (2 mL) at -78

°C to -30 °C under N₂ for 2 h. The solvent was then removed *in vacuo*.


Chromatography (SiO₂, 10% ethyl acetate/hexanes) gave the product (100 mg, 94 %) as a colourless oil. FABMS (NBA/NaI) 248 (M + H⁺ expected 248).

2.4 1-((*tert*-Butyloxy)carbonyl)-4-hydroxy-1,2,3,4-tetrahydroquinoline

5 3,4-epoxy-1-((*tert*-butyloxy)carbonyl)-1,2,3,4-tetrahydro-5,6-benzoquinoline (100 mg, 0.41 mmol) was treated with Dibal-H (91 mg, 0.62 mmol, 1.5 equiv) in THF (2 mL) at -78 °C under N₂. After 1 h, the reaction was quenched by the addition of water (2 mL) and the resulting solution was extracted with ethyl acetate (3 x 10 mL), the organic layers combined, dried and
10 concentrated. Chromatography (SiO₂, 10% ethyl acetate/hexanes) gave the alcohol (75 mg, 63%) as a colourless solid. FABMS (NBA/NaI) 250 (M + H⁺ expected 250).

2.5 1-((*tert*-Butyloxy)carbonyl)-4-chloro-1,2,3,4-tetrahydroquinoline

15 1-((*tert*-Butyloxy)carbonyl)-4-hydroxy-1,2,3,4-tetrahydroquinoline (100 mg, 0.40 mmol) in CH₂Cl₂ (2 mL) was treated with a prepared solution of PPh₃ (212 mg, 0.80 mmol, 2 equiv) and CCl₄ (500 µL) in CH₂Cl₂ (2 mL) at RT. After 16 h, the solvent was removed *in vacuo*. Chromatography (SiO₂, 10% ethyl acetate in hexanes) gave the chloride (65 mg, 61 %) FABMS (NBA/NaI) 268 (M + H⁺ expected 268). The compound could be conjugated
20 to a DNA binding subunit after deprotection by a method analogous to the steps of Example 3.4 below.

Example 3**3.1 2-bromo-N-(tert-Butoxy carbonyl) aniline (3.2)**

A solution of 2-bromoaniline (100 mg, 0.58 mmol), Boc-dicarbonate (507 mg, 2.32 mmol) and Et₃N (81 μ l, 0.58 mmol) in 1,4-dioxan (10 ml) was heated to 100°C under N₂ for 48 h. Upon completion, the resulting mixture was cooled, concentrated and purified by chromatography (SiO₂, EtOAc/ Hex 1:9) to afford 2 (116 mg, 73 %) as a clear film. ¹H NMR (CDCl₃, 500 MHz) FABMS (NBA/NaI): 271 (M + H⁺ expected 271), 295 (M + Na⁺ expected 295).

3.2 2-Bromo-N-(tert-butyloxycarbonyl)-N-(3-chloro-2-propen-1-yl) aniline (3.3)

A solution of 3.2 (350 mg, 1.29 mmol) in DMF (7 ml) was cooled to 0°C and NaH (93 mg, 3.85 mmol) was added. The resulting mixture was stirred for 15 mins and 1,3 dichloropropene (358 μ l, 3.85 mmol) was added. The mixture was allowed to warm to 25 °C and stirred for 15 h. The mixture was then concentrated. H₂O (10 ml) was added to the residue and the solution was extracted with EtOAc (3 x 10ml). The combined organic layers were dried with MgSO₄ and concentrated. The residue was purified by flash

chromatography (SiO₂, EtOAc/ Hex 1:9) to afford 3.3 (400 mg, 89 %) as a pale yellow oil. FABMS (NBA/NaI) 346 (M + H⁺ expected 346).

3.3 1-(*tert*-Butyloxycarbonyl)-3-(chloromethyl)indoline (3.4)

A solution of 3.3 (110 mg, 0.318 mmol) and AIBN (21 mg, 0.127 mmol) in dry
5 toluene (10 ml) was degassed for 15 mins with N₂ and then heated to 90°C. Bu₃SnH (84 µl, 0.318 mmol) was added to the mixture in four portions over an hour and the resulting mixture was stirred at 90 °C for a further 2 h. The mixture was then concentrated and purified by flash chromatography (SiO₂, 0-10% EtOAc in hexane) to afford 3.4 (50mg, 59%) as a colourless oil. FAB
10 MS: (NBA/NaI) 267, (M + H⁺, expected 267) 292 (M + Na⁺, expected 292).

3.4 3- (Chloromethyl)-1--[(5-methoxyindol-2-yl)carbonyl]indoline (3.5)

Compound 3.4 (100 mg, 0.38 mmol) was treated with 2.5 M HCl in EtOAc (1 mL) and the solution was stirred for 30 min. The solvent was removed under a stream of nitrogen and the grey residue was dissolved in DMF (10 mL). 5-
15 Methoxyindole-2-carboxylic acid (215 mg, 1.14 mmol) and EDC (215 mg, 1.14 mmol) were added and the mixture stirred for 16 h. Solvent was removed *in vacuo* and the residue subjected to flash chromatography (SiO₂, EtOAc/hexanes 1:1) to give the product as a red oil (100 mg, 76 %). FABMS (NBA/NaI) 341 (M + H⁺ expected 341).

20

Example 4 Biological testing of 3- (Chloromethyl)-1--[(5-methoxyindol-2-yl)carbonyl]indoline

Materials and Methods

4.1 Incubation mixtures of test compound and microsomes

25 Test compound activation by CYP enzymes was carried out using NADPH supplemented rat liver microsomes. Incubation mixtures comprised microsomal protein (1 mg/ml), reduced-nicotinamide adenine dinucleotide phosphate (NADPH, 10mM) and phosphate buffer (pH7.4, 100mM). Test compound (0.01 – 100 µM final concentration) in DMSO (20µl) was added to
30 the microsomal incubation mixtures (0.5ml) and incubated for 60 min at 37C. Control incubates contained test compound and microsomal incubation

mixture terminated at 0 time. All incubations were terminated by addition of an equal volume of ice-cold acetonitrile and microfuged for 3 min. Aliquots of the supernatant were added to cells in culture.

4.2 Cell culture based cytotoxicity measurement

Chinese Hamster Ovary (CHO) cell were grown in MEM supplemented with 10% dialysed FBS and G418 (400 μ g/ml). All cells were seeded at an initial density of 1000 cells/well in 96-well-plates, incubation at 37°C for 24 hours. Aliquots (0.1 ml) of the test compound/microsomal/acetonitrile supernatant was then added to the CHO cells. Cells were then incubated for 24 hours at 37°C, 5% CO₂. After this time period MTT (50 μ l; 2mg/ml stock solution) was added to each well and cells were incubated for a further 4 hours. During this time period MTT, a hydrogen acceptor tetrazolium salt, is reduced to formazan dye by mitochondrial dehydrogenase of viable cells. The media was aspirated from cells and DMSO (100 μ l/well) added to solubilise the coloured formazan dye. Absorbance of the formazan dye in the 96-well-plates was then determined at 550nm. The effect of microsomal activation by the test compound on the arrest of CHO cell growth could be determined by comparing the IC₅₀ (concentration that inhibited cell growth by 50%) with and without microsomal incubation.

Results

compound	CHO IC ₅₀ (μ M)		AF
	+activation	-activation	
3.5	0.13 \pm 0.03	5.51 \pm 0.23	42.4*

Effect of compound **3.5** and its metabolism (activation) product on the survival of Chinese hamster ovary cells in culture. Cells were incubated for 24 hours with supernatants from reaction mixtures of compound **3.5** with NADPH fortified rat liver microsomes. IC₅₀ represents the concentration of drug required to inhibit cell growth by 50%. Values are expressed as the mean \pm sd for three experiments. See methods for full details of metabolism.

AF = activity factor i.e. the ratio of IC₅₀ cytotoxicity values obtained for \pm compound **3.5** activation



* represents significance at $p > 0.05$.

5

10

CLAIMS

1. Use of a compound of the general formula I or IA or a salt thereof in the manufacture of a composition for use in a method of treatment by therapy of an animal:



in which X is H, X is H;

Y is a leaving group;

R¹ is -Ar, NH₂, or R⁸;


20 R², and R³ are each independently selected from H, C₁-₄ alkyl, -OH, C₁-₄ alkoxy, -CN, Cl, Br, I, -NO₂, -NH₂, -NHCOR⁹, -COOH, CONHR¹⁰, -NHCOOR¹⁰ and -COOR¹⁰;

R⁴ is selected from H, C₁-₄ alkyl, CN, Cl, Br, I, NO₂, NH₂, -NHCOR⁹, -COOH, -CONHR¹⁰, -NHCOOR¹⁰ and -COOR¹⁰;

25 R⁸, R⁹ and R¹⁰ are independently selected from C₁-₄ alkyl, optionally substituted phenyl, C₇-₁₂-aralkyl, optionally substituted heteroaryl and ligands;

Ar is selected from

25



in which B is N or CR¹⁴;

Z is O, S -CH=CH- or NH;

the or each R¹¹ is selected from OH, C₁₋₄ alkoxy, C₁₋₄ alkyl, -NO₂, -
 15 NH₂, -NHR¹⁷, -NR¹⁷₂, -N⁺R¹⁷₃, -CN, Cl, Br, I, -NHCOR¹⁵, -COOH, -CONHR¹⁶, -
 NHCOOR¹⁶ and -COOR¹⁶;

n is an integer in the range 0 to 4;

R¹² is H, -COAr¹, -CONH₂, -COOH, -COR¹⁶ or -COOR¹⁶;

the or each R¹³ is selected from OH, C₁₋₄ alkoxy, C₁₋₄ alkyl, -NO₂, -
 20 NH₂, -NHR¹⁷, -NR¹⁷₂, -N⁺R¹⁷₃, -CN, Cl, Br, I, -NHCOR¹⁵, -COOH, -CONHR¹⁶, -
 NHCOOR¹⁶ and -COOR¹⁶;

m is 0, 1 or 2;

R¹⁴ is selected from OH, C₁₋₄ alkoxy, C₁₋₄ alkyl, -NO₂, -NH₂, -CN, Cl,
 Br, I, -NHCOR¹⁵, -COOH, -CONHR¹⁶, -COOR¹⁶, -NHCOOR¹⁶ and H;

25 R¹⁵ is selected from C₁₋₄ alkyl, optionally substituted phenyl, optionally
 substituted heteroaryl, C₇₋₁₂ aralkyl, a ligand and Ar¹;


R¹⁶ is selected from C₁₋₄ alkyl, optionally substituted phenyl, C₇₋₁₂-
 aralkyl and optionally substituted heteroaryl and a ligand;

each R¹⁷ is selected from C₁₋₄-alkyl, optionally substituted phenyl,
 30 optionally substituted heteraryl and C₇₋₁₂-aralkyl; and

Ar¹ is selected from the same groups as Ar, and provided that no
 more than one group R¹¹ or R¹³ in any one ring includes a group Ar¹.


2. Use according to claim 1 in which the animal is a human.
3. Use according to claim 1 or claim 2 in which the treatment is of a tumour.
4. Use according to any preceding claim in which Y is selected from -OCOOR⁵, -OCONHR⁶, Cl, Br, and -OSOOR⁷, in which R⁵, R⁶ and R⁷ are independently selected from C₁₋₄ alkyl, optionally substituted phenyl, C₇₋₁₂-aralkyl and optionally substituted heteroaryl; preferably Cl.
5. Use according to any preceding claim in which Ar¹ is

10



15

6. Use according to any preceding claim in which R¹ is Ar.
7. Use according to claim 6 in which Ar is a group




20

8. Use according to claim 7 in which n is at least one and one of the groups R¹¹ of the Ar group is -NHCOAr¹.

9. Use according to claim 8 in which Ar¹ is a group

25




10. Use according to claim 9 in which, in Ar¹, n is at least 2 and R¹¹ is other than -NHCOAr¹, or n is 0.


30

11. Use according to claim 6 in which Ar is a group

27



12. Use according to claim 11 in which R^{12} is $-COAr^1$.
 13. Use according to claim 12 in which Ar^1 is a group



14. Use according to claim 13 in which, in Ar^1 , R^{12} is other than $-COAr^1$.

15. Use according to any preceding claim in which R^2 is H.
 16. Use according to any preceding claim in which R^3 is H.
 17. Use according to any preceding claim in which R^4 is H.
 18. A compound of the general formula I as defined in any of claims 1 and 4 to 17 for use in the treatment an animal by therapy.
 19. A compound according to claim 18 selected from:
 1-(chloromethyl)-6-benzoyl-3-((5-methoxy-1*H*-indol-2-yl)carbonyl)-1,2-dihydro-3*H*-pyrrolo[3,2-*e*]indole; and

- 3- (chloromethyl)-1--[(5-methoxyindol-2-yl)carbonyl]indoline.

20. A pharmaceutical composition comprising a compound of the general formula I as defined in any of claims 1 and 4 to 17 and a pharmaceutically acceptable excipient.

21. A compound of the formula IA as defined in any of claims 1 and 4 to 17.

22. A compound according to claim 21 which is
1-((5-methoxy-1H-indol-2-yl) carbonyl)-4-chloro-1,2,3,4-
tetrahydroquinoline.

23. A compound according to claim 21 or claim 22 for use in the
5 treatment of an animal by therapy.

24. A pharmaceutical composition comprising a compound
according to claim 21 or claim 22 and a pharmaceutically acceptable
excipient.

INTERNATIONAL SEARCH REPORT

ational Application No

PCT/GB 02/00785

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/47 A61K31/40 C07D215/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 702 004 A (CIBA GEIGY AG) 20 March 1996 (1996-03-20) page 13, line 9-40; claim 8; examples 1-160 ---	1-24
X	EP 0 461 603 A (KYOWA HAKKO KOGYO KK) 18 December 1991 (1991-12-18) the whole document --- -/--	1-24

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

6 June 2002

Date of mailing of the international search report

17/06/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Engl, B

INTERNATIONAL SEARCH REPORT

ational Application No

PCT/GB 02/00785

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>BOGER D L ET AL: "DUOCARMYCIN-PYRINDAMYCIN DNA ALKYLATION PROPERTIES AND IDENTIFICATION, SYNTHESIS, AND EVALUATION OF AGENTS INCORPORATING THE PHARMACOPHORE OF THE DUOCARMYCIN-PYRINDAMYCIN ALKYLATION SUBUNIT. IDENTIFICATION OF THE CC-1065-DUOCARMYCIN COMMON PHARMACOPHORE" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 112, 1990, pages 8961-8970, XP002058066 ISSN: 0002-7863 the whole document</p> <p style="text-align: center;">---</p>	1-24
Y	<p>BOGER D L ET AL: "SYNTHESIS AND EVALUATION OF CC-1065 AND DUOCARMYCIN ANALOGUES INCORPORATING THE ISO-CI AND ISO-CBI ALKYLATION SUBUNITS: IMPACT OF RELOCATION OF THE C-4 CARBONYL" JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 62, no. 25, 1997, pages 8875-8891, XP000915623 ISSN: 0022-3263 the whole document</p> <p style="text-align: center;">----</p>	1-24
Y	<p>BOGER D L ET AL: "DESIGN, SYNTHESIS, AND EVALUATION OF CC-1065 AND DUOCARMYCIN ANALOGS INCORPORATING THE 2,3,10,10A-TETRAHYDRO-1H-CYCLOPROPAUD BENZOUFQUINOL-5-ONE (CBQ) ALKYLATION SUBUNIT: IDENTIFICATION AND STRUCTURAL ORIGIN OF SUBTLE STEREOELECTRONIC FEATURES THAT GOVERN REACTIVITY AND REGIOSELECTIVITY" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 116, no. 25, 1994, pages 11335-11348, XP002914133 ISSN: 0002-7863 the whole document</p> <p style="text-align: center;">----</p>	1-24
Y	<p>ATWELL G J ET AL: "Synthesis and cytotoxicity of amino analogues of the potent DNA alkylating agent seco-CBI-TMI" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 7, no. 12, 17 June 1997 (1997-06-17), pages 1493-1496, XP004136243 ISSN: 0960-894X the whole document</p> <p style="text-align: center;">-----</p>	1-24

INTERNATIONAL SEARCH REPORT

II International Application No

PCT/GB 02/00785

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0702004	A	20-03-1996	AU 3053495 A	28-03-1996
			CA 2158227 A1	16-03-1996
			CN 1169986 A	14-01-1998
			CZ 9502365 A3	15-05-1996
			EP 0702004 A2	20-03-1996
			FI 954255 A	16-03-1996
			HU 74453 A2	30-12-1996
			JP 8176087 A	09-07-1996
			NO 953629 A	18-03-1996
			NZ 272999 A	27-07-1997
			US 5719141 A	17-02-1998
			ZA 9507726 A	15-03-1996

EP 0461603	A	18-12-1991	EP 0461603 A1	18-12-1991
			JP 4226988 A	17-08-1992
			US 5248692 A	28-09-1993
			US 5214065 A	25-05-1993
